Dicer and microRNA expression in multiple sclerosis and response to interferon therapy

Area of Science:

• Neuroimmunology
• Molecular Biology
• Biochemistry

Background:

• MicroRNA (miRNA) dysregulation is implicated in multiple sclerosis (MS) pathogenesis, but underlying mechanisms and therapeutic impacts remain unclear.
• Dicer, an enzyme crucial for mature miRNA biogenesis, is dysregulated in various diseases and its role in MS requires further investigation.
• Interferons (IFNs) are known to regulate Dicer in vitro, prompting investigation into their effect on Dicer expression in MS patients.

Purpose of the Study:

• To investigate the effect of interferon beta-1a (IFNβ1a) treatment on Dicer expression and miRNA profiles in patients with multiple sclerosis.
• To identify potential miRNA biomarkers associated with different MS subtypes and response to IFNβ1a therapy.

Main Methods:

• Dicer mRNA and protein levels, along with miRNA expression, were quantified in peripheral blood lymphocytes (PBL) from MS patients and healthy controls.
• Acute responses to IFNβ1a were assessed in a cohort of 50 MS patients.

Main Results:

• Dicer protein levels were decreased in MS patients compared to controls, while mRNA levels showed no significant difference.
• IFNβ1a treatment selectively induced both Dicer mRNA and protein levels in patients who responded well to the therapy.
• Distinct miRNA expression profiles were identified, potentially serving as biomarkers for relapsing remitting MS (RRMS), secondary progressive MS (SPMS), and IFNβ1a response.

Conclusions:

• Dicer dysregulation, particularly decreased protein levels, is associated with MS pathology.
• IFNβ1a therapy can modulate Dicer and miRNA expression in MS patients, highlighting Dicer as a potential therapeutic target.
• Identified miRNA signatures may offer insights into MS disease mechanisms and predict treatment response.